Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Hepatitis C 1Carcinoma, Hepatocellular 1

Interventions

Bevacizumab 69atezolizumab 54lenvatinib 42durvalumab 42Nivolumab 38pembrolizumab 35tremelimumab 28Magnetic Resonance Spectroscopy 21Specimen Handling 19tislelizumab 18sintilimab 17Ipilimumab 15Sorafenib 14regorafenib 13cabozantinib 13Radiosurgery 13Radiotherapy 12apatinib 11Blood Specimen Collection 11Immunoglobulin G 10camrelizumab 9Immune Checkpoint Inhibitors 9Disulfides 9X-Rays 8Cyclophosphamide 8donafenib 7Oxaliplatin 7Immunotherapy 7Folfox protocol 7Fluorouracil 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × elbasvir × 1 year × Clear all
NCT02940496 2025-07-15

Pembrolizumab (MK-3475) in Hepatocellular Carcinoma

M.D. Anderson Cancer Center

Phase 2 Completed
15 enrolled 8 charts
Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡